. 2021 Dec 2;16(4):464–475. doi: 10.4162/nrp.2022.16.4.464

Table 3. Partial Spearman’s correlation coefficients (r_s ) of homocysteine, cysteine, and IS with indicators of oxidative stress and glutathione-dependent antioxidant capacities in patients at different stages of chronic kidney disease¹⁾ .

Parameters		Homocysteine (mmol/L)	Cysteine (mmol/L)	IS (mmol/L)
Homocysteine (mmol/L)
	All (n = 132)	-	0.571^***	0.339^***
	Stage 1 (n = 21)	-	0.456	−0.378
	Stage 2 (n = 31)	-	0.512^**	−0.028
	Stage 3a (n = 31)	-	0.456^*	0.003
	Stage 3b (n = 20)	-	0.147	0.336
	Stage 4–5 (n = 29)	-	0.780^***	−0.000
Cysteine (mmol/L)
	All	0.571^***	-	0.240^**
	Stage 1 (n = 21)	0.456	-	0.069
	Stage 2 (n = 31)	0.512^**	-	−0.034
	Stage 3a (n = 31)	0.456^*	-	0.195
	Stage 3b (n = 20)	0.147	-	0.125
	Stage 4–5 (n = 29)	0.780^***	-	0.115
IS (mmol/L)
	All	0.339^***	0.240^**	-
	Stage 1 (n = 21)	−0.378	0.069	-
	Stage 2 (n = 31)	−0.028	−0.034	-
	Stage 3a (n = 31)	0.003	0.195	-
	Stage 3b (n = 20)	0.336	0.125	-
	Stage 4–5 (n = 29)	−0.000	0.115	-
MDA (mmol/L)
	All	−0.115	−0.331^***	−0.127
	Stage 1 (n = 21)	−0.163	0.066	0.573^*
	Stage 2 (n = 31)	0.131	−0.395	−0.32
	Stage 3a (n = 31)	0.270	−0.163	−0.204
	Stage 3b (n = 20)	−0.107	−0.243	−0.149
	Stage 4–5 (n = 29)	−0.511^*	−0.496^*	−0.247
ox-LDL (U/L)
	All	0.087	−0.073	0.171
	Stage 1 (n = 21)	0.115	−0.306	−0.273
	Stage 2 (n = 31)	0.115	−0.162	−0.065
	Stage 3a (n = 31)	0.122	−0.003	0.204
	Stage 3b (n = 20)	0.107	0.287	0.639^*
	Stage 4–5 (n = 29)	−0.056	−0.212	0.081
GSH/GSSG ratio
	All	0.168	0.215^*	−0.081
	Stage 1 (n = 21)	0.242	0.226	−0.020
	Stage 2 (n = 31)	0.367	0.165	−0.107
	Stage 3a (n = 31)	0.160	0.231	0.225
	Stage 3b (n = 20)	−0.134	0.175	−0.082
	Stage 4–5 (n = 29)	0.232	0.466^*	0.204
TEAC (mmol/L)
	All	0.146	0.097	0.078
	Stage 1 (n = 21)	0.142	0.325	0.329
	Stage 2 (n = 31)	0.248	0.242	−0.418^*
	Stage 3a (n = 31)	0.070	−0.232	−0.280
	Stage 3b (n = 20)	−0.321	−0.209	−0.680^**
	Stage 4–5 (n = 29)	−0.180	−0.179	0.012
GSH (mmol/L)
	All	0.159	0.221^*	−0.054
	Stage 1 (n = 21)	0.177	0.220	−0.061
	Stage 2 (n = 31)	0.407^*	0.240	−0.051
	Stage 3a (n = 31)	0.015	0.178	0.349
	Stage 3b (n = 20)	0.087	0.054	0.107
	Stage 4–5 (n = 29)	0.306	0.565^**	0.225
GSSG (mmol/L)
	All	0.085	0.144	0.059
	Stage 1 (n = 21)	0.169	0.212	−0.313
	Stage 2 (n = 31)	0.115	0.155	0.153
	Stage 3a (n = 31)	−0.083	0.163	0.233
	Stage 3b (n = 20)	0.325	−0.044	0.260
	Stage 4–5 (n = 29)	0.249	0.436^*	0.012
GSH-Px activity (nmol/mL/min)
	All	−0.496^***	−0.363^***	−0.219^*
	Stage 1 (n = 21)	−0.087	−0.206	0.317
	Stage 2 (n = 31)	−0.537^**	−0.350	0.002
	Stage 3a (n = 31)	−0.438^*	0.012	−0.318
	Stage 3b (n = 20)	−0.379	−0.310	−0.051
	Stage 4–5 (n = 29)	−0.555^**	−0.658^***	0.222

IS, indoxyl sulfate; MDA, malondialdehyde; ox-LDL, oxidized low density lipoprotein cholesterol; GSH, glutathione; GSSG, oxidized glutathione; TEAC, trolox equivalent antioxidant capacity; GSH-Px, glutathione peroxidase.

¹⁾Values are r_s , correlation coefficient. Adjusting for age, gender, body mass index, albumin, smoking and drinking habits.

^*P < 0.05, ^**P < 0.01, ^***P < 0.001.

Table 3. Partial Spearman’s correlation coefficients (rs ) of homocysteine, cysteine, and IS with indicators of oxidative stress and glutathione-dependent antioxidant capacities in patients at different stages of chronic kidney disease1) .

Table 3. Partial Spearman’s correlation coefficients (r_s ) of homocysteine, cysteine, and IS with indicators of oxidative stress and glutathione-dependent antioxidant capacities in patients at different stages of chronic kidney disease¹⁾ .